Compare Gilead Sciences, Inc. (GILD) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Plby Group Inc — how do they compare? Gilead Sciences, Inc. trades at $133.18 (market cap $163.51B), while Plby Group Inc trades at $1.11 (market cap $128.89M). The key difference: Gilead Sciences, Inc. is far larger — about 1268.6× Plby Group Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals.
| GILD | PLBY | |
|---|---|---|
Market Cap | $163.51B | $128.89M |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $2.71 |
52-Week Low | $108.22 | $1.11 |
Enterprise Value | $178.05B | $276.69M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Playboy (PLBY) trades at $1.17, showing no daily change, with technical indicators presenting a mixed but overall bearish picture. Fundamentally, the company demonstrates improving trends with five consecutive quarters of positive adjusted EBITDA, a narrowing net loss, and inclusion in the Russell 2000 and 3000 indices. Recent strategic moves include a significant share repurchase and board appointments. However, the balance sheet shows negative shareholder equity and high leverage, with a debt-to-asset ratio of 59.52% as of 2025.
The outlook is cautiously optimistic, driven by operational momentum and strategic focus, but significant risks remain. Investment opportunity lies in the continued execution of the turnaround plan, potential for sustained profitability, and brand revitalization. Key risks include the high debt burden, persistent negative equity, competitive pressures in the licensing and leisure sectors, and the challenge of translating operational improvements into consistent bottom-line profitability for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
